Development of a novel gene signature to predict prognosis and response to PD-1 blockade in clear cell renal cell carcinoma

Xiaomao Yin, Zaoyu Wang, Jianfeng Wang, Yunze Xu, Wen Kong, and Jin Zhang

Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

ABSTRACT

Clear cell renal cell carcinoma (ccRCC) is the most common kidney malignancy characterized by a poor prognosis. The treatment efficacy of immune checkpoint inhibitors (ICIs) also varies widely in advanced ccRCC. We aim to construct a robust gene signature to improve the prognostic discrimination and prediction of ICIs for ccRCC patients. In this study, adopting differentially expressed genes from seven ccRCC datasets in GEO (Gene Expression Omnibus), a novel signature (FOXM1&TOP2A) was constructed in TCGA (The Cancer Genome Atlas) database by LASSO and Cox regression. Survival and time-dependent ROC analysis revealed the strong predictive ability of our signature in discovery set, two online validation sets and one tissue microarray (TMA) from our institution. High-risk group based on the signature comprises more high-grade (G3&G4) and advanced pathologic stage (stageII/IV) tumors and presents hyperactivation of cell cycle process according to the functional analysis. Meanwhile, high-risk tumors demonstrate an immunosuppressive phenotype with more infiltrations of regulatory T cells (Tregs), macrophages and high expressions of genes negatively regulating anti-tumor immunity. Low-risk tumors have an improved response to anti-PD-1 therapy and the predictive ability of our signature is better than other recognized biomarkers in ccRCC. A nomogram containing this signature showed a high predictive accuracy with AUCs of 0.90 and 0.84 at 3 and 5 years. Overall, this robust signature could predict prognosis, evaluate immune microenvironment and response to anti-PD-1 therapy in ccRCC, which is very promising in clinical promotion.

Introduction

Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma (RCC) and responsible for the majority of RCC-related deaths.\(^1\) Surgical resection is recommended for patients with localized ccRCC and many of them possess favorable prognosis.\(^2\) However, 20–40% patients would experience tumor progression and death after curative intent surgery.\(^3\)\(^,\)\(^4\) Benefiting from better understandings of tumor immunogenicity and large numbers of clinical trials, several immune checkpoints inhibitors (ICIs) have been approved for metastatic ccRCC after targeted therapy failure (nivolumab) or in combination with targeted agents (pembrolizumab + axitinib/avelumab + axitinib) as the first-line therapy.\(^5\)\(^,\)\(^6\)\(^,\)\(^7\) Tumor immune microenvironment (TIME) which comprises infiltrated immune cells and immunomodulatory molecules has been revealed highly correlated with cancer progression and ICIs response.\(^8\)\(^–\)\(^10\) Thus, constructing a prognostic model with the power of evaluating TIME has a great potentiality of predicting clinical outcomes and immunotherapy response in ccRCC.

In recent years, some powerful multi-gene signatures have been developed to evaluate the postoperative risk or ICIs response for ccRCC. ClearCode34 is a mRNA classifier established from an institutional cohort and The Cancer Genome Atlas (TCGA) database. It demonstrated a satisfactory diagnostic performance over clinical nomograms with c-indices of 0.65–0.70.\(^11\) Rini and his colluges developed a 16-gene assay capable of predicting recurrence after surgery for localized ccRCC.\(^12\)\(^,\)\(^13\) Deep RNA-seq analysis constructed a B cell-related gene signature to predict efficacy of anti-PD-1 therapy in ccRCC.\(^14\) All of these mRNA-based signatures usually incorporated dozens of biomarkers detected by RNA sequencing or RT-PCR without validation by other types of data (such as microarray or tissue microarray), which might restrain their applications in clinical practice.

In this study, we integrally analyzed seven ccRCC datasets from Gene Expression Omnibus (GEO) and TCGA database to develop a robust signature, the predictive ability of which was validated in two independent cohorts online and one tissue microarray (TMA) cohort from our institution. This signature further demonstrated strong capacity of estimating TIME and response to immunotherapy in ccRCC. What’s more, in combination with clinicopathological features, a nomogram based on our gene signature presented improved predictive power and risk stratification for ccRCC.
Material and methods

Collection of ccRCC datasets

Microarray datasets applied to robust DEGs analysis were downloaded from GEO (http://www.ncbi.nlm.nih.gov/geo/). All included datasets met the following criteria: Gene expression data containing at least 10 human ccRCC and adjacent normal tissues. Seven ccRCC datasets were finally determined for our research: GSE53757, GSE53000, GSE36895, GSE15641, GSE66272, GSE68417, GSE40435. Clinical and RNA-seq data of ccRCC samples was downloaded from TCGA database (https://cancergenome.nih.gov/). E-MTAB-1980 dataset downloaded from ArrayExpress database (https://www.ebi.ac.uk/arrayexpress/) was served as validation set.

Tissue microarray (TMA) containing ccRCC and adjacent normal samples were collected from patients undergoing nephrectomy in Renji Hospital. Informed consent was obtained from all patients. Clinicopathologic information was collected during the follow-up after surgery. TNM stage was determined according to American Joint Committee on Cancer staging manual (7th edition), and pathological grade was evaluated according to the Fuhrman grading system. This was approved by the Ethics and Research Committees of Renji Hospital, Shanghai Jiao Tong University School of Medicine.

Robust DEGs identification

R packages “affy” or “oligo” were selected to conduct combination of original CEL file, RMA background correction and data normalization according to their compatibility with platforms.14,15 Package “limma” was utilized to find DEGs with the threshold set at log₂FoldChange > .585 and adjusted P < .05.16 Then, we utilized the robust rank aggregation (RRA) method to integrate the results of 7 GEO datasets to identify the robust DEGs.17

Co-expression modules construction and hub genes identification

Weighted Gene Co-expression Network Analysis (WGCNA) is a method capable of transforming expression data into co-expression gene modules and exploring the relationship between modules and phenotypic traits.18 In our study, top 3000 upregulated DEGs (according to P) were extracted from RRA analysis to perform WGCNA using the expression data of TCGA cohort. Scale independence and average connectivity degree of network with different power value were tested (ranging from 1 to 18). The appropriate power value was determined when scale independence was above 0.85 with relatively higher connectivity degree. Then, according to topological overlap matrix (TOM)-based dissimilarities, genes were sorted into different gene modules. The module with the highest correlation with clinical traits was regarded as key module and selected to identify candidate hub genes.

Hub genes were determined by the overlap of candidate hub genes and genes selected from protein–protein interaction (PPI) network.19 These genes were further validated in TCGA cohort. Genes which were upregulated in tumor and significantly correlated with overall survival (OS) of ccRCC patients (P < .01) were chosen for further analysis.

Signature construction

Least Absolute Shrinkage and Selection Operator regression (LASSO) is a form of penalized regression which could be used in screening variables from high dimensional data to construct risk models.20 In our study, patients in TCGA cohort were randomly divided into two group by 3:1 ratio, discovery set (n = 398) and internal validation set (n = 133). LASSO regression was performed on discovery set to find most valuable genes with prognostic power in ccRCC. Optimal value of tuning parameter (λ) were determined by ten-time cross-validation using minimum criteria. Prognostic values of these genes were further validated on the TMA cohort. Multivariate cox regression was used to construct the gene signature. Based on the signature we built, a risk score formula was established as follows:

\[
\text{Riskscore} = \sum_i \text{Coefficient of (i)} \times \text{Expression of gene (i)}
\]

Coefficient of gene (i) is the regression coefficient of gene (i) in LASSO-Cox regression model and Expression of gene (i) is the expression value of Gene (i) for each patient. Patients were divided into high- and low-risk groups according to the median of risk score.

Enrichment analysis

Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed on genes in the key module by R package “clusterprofiler”.21 After setting the criteria of adjusted P < .01, GO terms and KEGG pathways were visualized by package “ggplot2”.

We utilized the package “clusterprofiler” to conduct Gene Set Enrichment Analysis (GSEA) analysis for signature genes.21 Meanwhile, the “GSVA” package was used to find significantly correlated pathways.22 adjusted P < .01 was regarded as statistical significance. The gene set “c2.cp.kegg.v6.2.symbols.gmt” and “h.all.v7.2.symbols.gmt” was chosen as the reference gene set.

Nomogram construction

We performed univariate analysis on clinicopathologic parameters and our signature in the TMA cohort. The significant prognostic variables (P < .05) were subsequently incorporated into multivariate Cox regression analysis. R package “rms” was utilized to build the nomogram adopting variables with predictive significance in multivariate analysis (P < .05). Calibration curves were used to assess the consistency between predicted and actual survival outcome. Furthermore, time-dependent ROC curves were applied to compare the predictive accuracy of nomogram, gene risk model and clinicopathologic factors.

Immune infiltration analysis

CIBERSORT, IMMUNECII AI and ESTIMATE were used to estimate immune cells abundance between high- and low-risk
groups using expression data from TCGA database. Immune-related molecules were further analyzed to understand immune infiltration in ccRCC.

Response to anti-PD-1 therapy

Clinical and RNA-seq data were retrieved from two clinical trials: 1) a phase III study of nivolumab vs. everolimus in patients with previously treated metastatic RCC (CheckMate 025, NCT01668784); 2) a phase II study of metastatic RCC patients treated with nivolumab (CheckMate 010, NCT01354431). Details on study designs and treatment for patients in each trial have been published before. Metastatic ccRCC patients treated with nivolumab were collected to evaluate the predictive ability of our signature.

Somatic variants analysis

Genetic mutation data were downloaded from TCGA database. The “maftools” package was used to analyze somatic variants. The overall mutation status was depicted in high- and low-risk groups. Top five mutated genes were also compared between two risk groups.

Immunohistochemistry (IHC)

The primary antibodies used in IHC for TMA slides were as follows: anti-FOXM1 (Proteintech, #13147-1-AP, 1:100 dilution), anti-TOP2A (Santa Cruz, sc365916, 1:50 dilution), anti-NUF2 (Bioss, bs-77714 R, 1:100 dilution), anti-KIF18B (Novus, #NBP1-90882, 1:50 dilution). TMAs were stained according to the conventional streptavidin-peroxidase method of IHC (Zymed Laboratories Inc, San Francisco, CA, USA). Two certified pathologists who were blind to the information of patients independently analyzed the IHC results. At high (200×) magnification, the percentage of positive cells was scored as: 1 (0–25%), 2 (26–50%), 3 (51–75%), 4 (>75%). The intensity of positive staining was classified into 4 scales: 0 (negative), 1 (weak), 2 (moderate), 3 (strong). Then, comprehensive score (staining percentage × intensity) was used to evaluate the expression level of signature genes. Disagreements between two pathologists were resolved by consensus. Comprehensive score = 6 was set as cutoff value to define high and low expression group of signature genes.

Multiplex immunohistochemistry (mIHC)

Staining of TMA slides was performed with the autostainer system Bond III (Leica Biosystems, Austria). Primary antibodies are as follows: anti-CD68 (Gene Tech, #GM087602, 1:100 dilution), anti-CD163 (ABCAM, #ab182422, 1:300 dilution), anti-FOXP3 (R&B, #MAB8214, 1:100 dilution), anti-PD-L1 (CST, #13684, 1:400 dilution). Each slide was scanned with the Pannoramic MIDI (3DHISTECH, Hungary). Multispectral images were evaluated using HALO Image Analysis Platform (Version 2.3.2089.52, Indica Labs, US). Individual cells were identified using the DAPI nucleus staining. Treg cell (FOXP3 +), Macrophage (CD68+), Macrophage M2 (CD68+/CD163+) and PD-L1 positive cells were quantified and their percentages in each TMA core were calculated.

Results

Identification of robust DEGs

The design of our study is shown in Figure 1. The information of 7 ccRCC GEO datasets included in current study is displayed in Table S1. RRA could combine and rank multiple lists of DEGs derived from datasets measured by different platforms. A total of 266 ccRCC samples and 343 peritumor tissues were incorporated into RRA analysis to identify the robust DEGs. The expression pattern of top 20 upregulated and downregulated robust DEGs demonstrated high consistency in different datasets (Figure S1).

Identification of the key module and hub genes

To find the key module most correlated with clinical traits, we performed WGCNA on TCGA cohort extracting robust DEGs derived from the RRA analysis. Clinical information was retrieved from TCGA (Figure 2a). After setting soft-thresholding value as 6 (scale free R2 = .87, mean connectivity = 11.10) and cut height as 0.20, eight co-expression modules were eventually identified (Figure 2b-d). According to the heat-map of module-trait relationships, green module demonstrates the highest correlations with clinical traits (Figure 2e; R2 = .35 and P = 2e-16 with pathologic stage, R2 = .38 and P = 6e-20 with tumor grade, R2 = .31 and P = 2e-13 with vital status). Module significance analysis further validated that green module is the highest correlated module with survival status of ccRCC patients (Figure 2f). Herein, we determined green module as the key module. GO and KEGG analyses were conducted to obtain further insight into biological function of genes within the key module. Based on adjust P value, top ten significant GO terms for biological process, molecular function and cellular component, as well as KEGG pathways, are shown in Figure S2. The results implied that genes in the key module are mainly involved in mitotic cell cycle, nuclear division and organelle fission.

Hub genes were recognized as the overlap of candidate hub genes and gene in MCODE sub module. Under the thresholds of Module Membership > 8 and Gene Significance > .2, 53 candidate genes in green module were extracted (Figure S3A). 105 genes were chosen from PPI network after MCODE analysis and visualized by Cytoscape (Figure S3B). Forty nine hub genes were eventually identified after mapping candidate genes to MCODE genes. These hub genes were listed in Table S2. The up-regulation of hub genes in tumors was confirmed by independent samples t-test (P < .01, Table S3 & Figure S4). These genes were further performed Kaplan-Meier survival analysis on GEPIA website (http://gepia.cancer-pku.cn/). Twenty four hub genes highly correlated with OS of ccRCC patients were chosen for further analysis (P < .01, Table S3 & Figure S5).

Construction of the gene signature

LASSO regression was performed on 24 validated hub genes in discovery set and 4 biomarkers: FOXM1 (Forkhead box M1),
TOP2A (DNA Topoisomerase IIα), KIF18B (Kinesin Family member 18B), NUF2 (NUF2 component of NDC80 kinetochore complex) were preserved when the tuning parameter (λ) was minimized to 0.038 and log(λ) was −3.25 (Figure 3a). Immunostaining of these genes was performed on TMA containing 348 ccRCC tumors and peritumor tissues from our institution. Detailed information of patients in the TMA is shown in Table 1. The representative images of four genes expressed in tumors and peritumor tissues are shown in Figure 3c. The result showed all genes were significantly upregulated in tumors from TCGA cohort (P < .001) (Figure 3b). IHC staining revealed protein levels of FOXM1, TOP2A and NUF2 were significantly higher in tumors compared with peritumor tissues (P < .001). While the protein level of KIF18B was reversely upregulated in peritumor tissues (P < .001) (Figure 3d). Furthermore, survival analysis showed that high expressions of FOXM1 and TOP2A were significantly correlated with shortened OS in the TMA cohort (P < .001, Figure 3e). Finally, TOP2A and FOXM1 were incorporated into the Cox proportional hazard model and risk score = (0.693 \times \text{FOXM1 expression}) + (−0.184 \times \text{TOP2A expression}). According to the median of risk score, patients were divided into high- and low-risk groups.
Validation of the gene signature

To evaluate the predictive abilities of our signature, we performed Kaplan-Meier survival and time dependent ROC analysis in discovery (n = 398), internal (n = 133) and two external validation sets (E-MTAB-1980, n = 101; TMA cohort, n = 348). In discovery set, high-risk group comprised more death cases than low-risk group (Figure 4a, left panel). The survival rate of patients in high-risk group was significantly lower than those in low-risk group (P < .0001, Figure 4a, middle panel). The predictive accuracy of this signature was 0.68, 0.70 and 0.70 at 3, 5 and 8 years (Figure 4a, right panel). In accordance with the results in discovery set, a lower survival rate was observed in high-risk group, both in internal validation set (P = .029, Figure 4b, middle panel) and two external validation sets (P < .0001, Figure 4c, middle panel; P < .0001, Figure 4d, middle panel). In internal validation set, the predictive accuracy of the gene signature was 0.63, 0.66 and 0.76 at 3, 5 and 8 years (Figure

Figure 2. Identification of the key module by WGCNA. (a) Clustering dendrogram of ccRCC samples and heatmap of clinical traits. The clustering was based on the expression data of robust DEGs. The color intensity in heatmap increased with age, pathological stage and grade. In terms of survival status, white means alive and red means dead. (b) Analysis of the scale-free fit index (left) and the mean connectivity (right) for various soft-thresholding power value. (c) Clustering of module eigengenes. The red line indicates cut height = 0.20. (d) Dendrogram of all DEGs clustered based on a dissimilarity measure (1-TOM) together with assigned module colors. (e) Heatmap of the correlation between module eigengenes and clinical traits of ccRCC. Each cell contains the Pearson correlation coefficient and P value. (f) Distribution of average gene significance and errors in the modules associated with survival status of ccRCC. ccRCC, clear cell renal cell carcinoma; DEGs, differentially expressed genes; TOM, topological overlap matrix; WGCNA, Weighted Gene Co-expression Network Analysis.
4b, right panel). In external validation sets, this signature also had a good performance in predictive accuracy (AUC: 0.76, 0.67 and 0.72 at 3, 5 and 8 years, Figure 4c, right panel; AUC: 0.72, 0.75 and 0.74 at 3, 5 and 8 years, Figure 4d, right panel).

**High-risk group correlates with higher tumor grade and advanced pathologic stage**

Significant differences were found between high- and low-risk groups in tumor grade and pathologic stage. High-risk group comprised more high-grade tumors (G3&G4) than low-risk group (62.5% vs. 45.0% in TCGA cohort, \( P < .001 \); 66.7% vs. 17.9% in combined GEO cohort, \( P < .001 \); 36.0% vs. 18.4% in E-MTAB-1980 cohort, \( P = .049 \); 28.2% vs. 6.9% in TMA cohort, \( P < .001 \); Figure 5a). With respect to the distribution of pathologic stage, patients in high-risk group also underwent significant upstaging compared with those in low-risk group (49.8% vs. 28.2% in TCGA cohort, \( P < .001 \); 66.7% vs. 33.3% in combined GEO cohort, \( P = .032 \); 39.2% vs. 10.0% in E-MTAB-1980 cohort, \( P < .001 \); 8.6% vs. 1.1% in TMA cohort, \( P < .001 \); Figure 5b).

Relationships between clinicopathologic features and TOP2A/FOXM1 expressions were also investigated respectively in the TMA cohort. The results indicated that expression of FOXM1 was correlated with age (\( P = .012 \)), AJCC stage (\( P = .015 \)), grade (\( P < .001 \)), tumor size (\( P < .001 \)) and necrosis (\( P = .003 \)), expression of TOP2A was correlated with grade
Table 1. Clinical and pathologic features of 348 ccRCC patients in TMA cohort.

| Features          | n(%) |
|-------------------|------|
| Age, n(%)         |      |
| ≤65               | 266  (76.4%) |
| >65               | 82   (23.6%) |
| Tumor size (cm)   |      |
| ≤4                | 179  (51.4%) |
| >4                | 169  (48.6%) |
| Gender, n(%)      |      |
| Male              | 245  (70.4%) |
| Female            | 103  (29.6%) |
| AJCC stage, n(%)  |      |
| I                 | 276  (79.3%) |
| II                | 55   (15.8%) |
| III               | 10   (2.8%) |
| IV                | 7    (2.1%) |
| Fuhrman grade, n(%)|    |
| I                 | 114  (32.8%) |
| II                | 173  (49.7%) |
| III               | 55   (15.8%) |
| IV                | 6    (1.7%) |
| Tumor Necrosis, n(%)|    |
|                   | 62   (17.8%) |
| Death during follow-up, n(%)| 71   (20.7%) |

ccRCC: clear cell renal cell carcinoma; TMA: tissue microarray

(P < .001), tumor size (P = .002) and necrosis (P < .001) (Table 2). Representative pictures depicted correlations between TOP2A/FOXM1 expressions and tumor grade is shown in Figure 5c, the staining intensities of TOP2A and FOXM1 gradually increased with advancing tumor grade. These results indicate these two genes may be closely related to cell cycle process.

**GSEA and GSVA confirm the high correlation between signature genes and cell cycle procession in ccRCC**

To reveal the underlying mechanism of TOP2A and FOXM1 in ccRCC progression, we performed GSEA and GSVA on RNA-seq data of TCGA cohort. Top three significantly enriched pathways are demonstrated in Figure 5d-e. Genes in high expression groups of TOP2A and FOXM1 were all enriched in “Cell cycle” and “Homologous recombination”. GSVA confirmed that gene sets of “Cell cycle”, “Homologous recombination”, “DNA replication” and “Mismatch repair” were significantly upregulated in the high expression group of signature genes (Figure 5f-g). Moreover, high-risk group has significant upregulation of cell cycle pathways, for example, “G2M checkpoint”, “E2F targets”, “Mitotic spindle” and “MYC targets” (Figure 5S). Thus, ccRCC in high-risk group presents upregulated cell cycle procession which might contribute to the hyperproliferation of tumor cells and dismal outcomes.

**Immune landscape between high- and low-risk ccRCC**

To evaluated whether this cell cycle-related signature could reflect the tumor immune microenvironment, we estimated the infiltration of immune cells in ccRCC through ESTIMATE, CIBERSORT and IMMUNECELL AI, three independent algorithms. ESTIMATE score and immune cell types which were differentially infiltrated between low- and high-risk groups were presented in Figure 6a. High-risk group with significantly higher immune_score indicated more immune cells infiltration (P < .001). Moreover, high-risk tumors contained higher level of immune suppressive cells (T follicular helper cells, regulatory T cells (Tregs), Macrophages, etc). By comparing the results of CIBERSORT and IMMUNECELL AI, regulatory T cells (Tregs) and Macrophages were both significantly upregulated in high-risk group (Figure 6b), which indicated an immunosuppressive phenotype might exist in those tumors.

**High-risk tumors show immunosuppressive phenotype**

To confirm the immune cell abundance inferred by two algorithms, we performed mHIC on TMA to identify infiltrations of Macrophages and Tregs in ccRCC. In accordance with the immune infiltration analysis, proportions of Macrophages (CD68+) infiltrated in high-risk tumors were significantly higher than those in low-risk group (P = .035). FOXP3 + Tregs also presented the same trend (P = .005). Moreover, M2 Macrophages (CD68+ CD163+) were also markedly increased in high-risk group (P = .015)(Figure 6c). Representative immunofluorescence staining pictures of high- and low-risk tumors were showed in Figure 6d. These results further validated more immune suppressive cells infiltrated in high-risk tumors. In addition, PD-L1 expression was also detected in the TMA. PD-L1 positive tumors (PD-L1 positive cell >1%) accounted for 5.9% of all tumors and there was no difference in PD-L1 expression between high- and low-risk tumors (11 positive tumors vs. 9 positive tumors) (Figure 6c).

To further validate the immunosuppressive phenotype, we investigated immune molecules which negatively regulated the anti-tumor immune response. Expression data of genes negatively regulating The Cancer-Immunity Cycle were download from Tracking Tumor Immunophenotype website (http://biocc.hrbmu.edu.cn/) and analyzed by high- and low-risk groups. The results showed that genes involved in the negative regulation of the Cancer-Immunity Cycle were essentially upregulated in high-risk group, indicating high-risk patients have low activities of antitumor immune processes (Figure 6e). Common immune checkpoints, such as PD-1, PD-L1, CTLA-4 and LAG3, were compared between two groups. The results showed that PD-1, CTLA-4 and LAG3 were significantly overexpressed in high-risk group compared to the counterpart (P < .001)(Figure 6f). Chemokines involved in immunosuppressive process induced by Macrophages and Tregs (IL-4, IL-10, IL-13, TGF-β) were also significantly upregulated in high-risk group (P < .001)(Figure 6g). These data suggest high-risk patients exhibit inertia in antitumor immunities, which might contribute to their poor prognosis.

**Low-risk patients are associated with increased response to anti-PD-1 immunotherapy**

In light of the correlation between our signature and immunologic activity in ccRCC, we next investigated whether there was a correlation between the signature and immunotherapy response. 156 advanced ccRCC patients treated with nivolumab (anti-PD-1 agent) were retrieved for analysis. Patients classified into clinical benefit (CB), intermediate clinical benefit (ICB) and no clinical benefit (NCB) groups were 53, 44 and 59, respectively. Distribution of high- and low-risk patients among
three groups was shown in Figure 7a. ICB patients were included into the CB group for subsequent analysis. The results showed low-risk patients were enriched in CB versus NCB group (57.7% vs. 37.3%, \( P = .013 \), Figure 7b). Meanwhile, significantly prolonged progression-free survival (PFS) was observed in low-risk patients compared to high-risk ones (\( P = .0031 \), Figure 7c).

To compare the predictive value of this gene signature and other biomarkers of immunotherapy response, PD-L1, tumor mutation burden (TMB) and PBRM1 (Polybromo 1) mutations were also involved in analysis.\(^{28,36–38}\) There were no differences in PD-L1 expression level and TMB between CB and NCB group (\( P = .71 \), Figure 7d; \( P = .27 \), Figure 7f). PBRM1 mutations were more likely to cluster in CB versus NCB group, but significance was not detected (35.5% vs. 26.3%, \( P = .34 \), Figure 7e). These results indicate our signature has a potent predictive ability in immunotherapy response and better than other recognized biomarkers.

**Analysis of somatic variants**

Somatic mutations in high- and low-risk ccRCC tumors were also investigated. Differences of mutation landscapes between two groups were depicted in Figure 8a-b. VHL, PBRM1, TTN,
and SETD2 were the most commonly mutated genes (>10% mutation rate) both in high- and low-risk tumors. The mutation rate of BAP1 (BRCA1 associated protein 1) was significantly higher in high-risk group (17% vs. 5%, \( P < .001 \)) (Figure 8c).

Since PBRM1 loss of function (missense mutation, frameshift deletion, nonsense mutation, splice-site, etc.) was previously reported to correlate with ccRCC survival and response to ICIs,\(^{36,39}\) the correlation between PBRM1 LOF (loss of function) and this cell cycle-related signature was explored. The result showed percentage of PBRM1 LOF was higher in low-risk group than high-risk group (17% vs. 5%, \( P < .001 \)) (Figure 8c-d). Patients with PBRM1 LOF were found to have significantly prolonged OS compared to PBRM1 intact ones (\( P = .012 \), Figure 8e). Multivariate Cox regression analysis demonstrated both the cell cycle-related signature and

---

**Figure 5.** High correlations of the gene signature with tumor grade and pathologic stage followed by functional analysis of signature genes. (a) Distribution of G1&G2 and G3&G4 tumors between high- and low-risk group in TCGA, combined GEO (GSE66272 & GSE36895), E-MTAB-1980 and TMA cohort. (b) Distribution of stage I/II and III/IV tumors between high- and low-risk group in TCGA, combined GEO (GSE66272 & GSE36895), E-MTAB-1980 and TMA cohort. (c) Representative immunostaining pictures of FOXM1 and TOP2A between different tumor grade. Scale bar: 100 μm. Top 3 gene sets enriched in the high-expression group of signature genes (d) FOXM1 (e) TOP2A. Clustering heatmaps of differentially enriched pathways for signature genes based on GSVA. (f) FOXM1 (g) TOP2A. \( \chi^2 \) test was used to test difference in distribution of tumor grade and pathologic stage, \( *P < .05, **P < .01, ***P < .001 \). GEO, Gene Expression Omnibus; GSVA, gene set variation analysis; TCGA, The Cancer Genome Atlas; TMA, tissue microarray.
Table 2. Association of TOP2A and FOXM1 expression with clinicopathologic factors of ccRCC patients in TMA cohort.

| Factors          | TOP2A expression | FOXM1 expression |
|------------------|------------------|------------------|
|                  | Low (233/67%)    | High (115/33%)   | Low (182/52%) | High (166/48%) |
|                  |                  |                  | χ²     | P value       | χ²     | P value       |
| Gender           |                  |                  |        |               |        |               |
| Male             | 245              | 162 (66%)        | 83 (34%) | 0.26         | 0.611  | 125 (51%)    | 120 (49%)    | 0.54 | 0.461        |
| Female           | 103              | 71 (69%)         | 32 (31%) |               |        | 57 (55%)     | 46 (45%)     |      |              |
| Age              |                  |                  |        |               |        |               |               |      |              |
| ≤65              | 266              | 185 (70%)        | 81 (30%) | 3.44         | 0.064  | 149 (56%)    | 117 (44%)    | 6.25 | 0.012*       |
| >65              | 82               | 48 (59%)         | 34 (41%) |              |        | 33 (40%)     | 49 (60%)     |      |              |
| AJCC stage       |                  |                  |        |               |        |               |               |      |              |
| I+                | 331              | 225 (68%)        | 106 (32%) | 3.20         | 0.074  | 178 (54%)    | 153 (46%)    | 5.93 | 0.015*       |
| II+               | 17               | 8 (47%)          | 9 (53%)  |              |        | 4 (23%)      | 13 (77%)     |      |              |
| III+ IV          |                  |                  |        |               |        |               |               |      |              |
| Tumor size(cm)   |                  |                  |        |               |        |               |               |      |              |
| ≤4               | 179              | 133 (74%)        | 46 (26%) | 9.00         | 0.003* | 107 (60%)    | 72 (40%)     | 8.26 | 0.004*       |
| >4               | 169              | 100 (59%)        | 69 (41%) |              |        | 75 (44%)     | 94 (56%)     |      |              |
| Grade            |                  |                  |        |               |        |               |               |      |              |
| I+ II            | 287              | 208 (73%)        | 79 (27%) | 22.55        | <0.001*| 168 (58%)    | 119 (42%)    | 25.54 | <0.001*      |
| III+ IV          | 61               | 25 (41%)         | 36 (59%) |              |        | 14 (23%)     | 47 (77%)     |      |              |
| Necrosis         |                  |                  |        |               |        |               |               |      |              |
| Yes              | 62               | 26 (42%)         | 36 (58%) | 21.34        | <0.001*| 22 (36%)     | 40 (64%)     | 8.55  | 0.003*       |
| No               | 286              | 207 (72%)        | 79 (28%) |              |        | 160 (56%)    | 126 (44%)    |      |              |

ccRCC: clear renal cell carcinoma; TMA: tissue microarray

PBRM1 mutation status were independent risk factors of ccRCC survival (Figure 8f). Moreover, combination of PBRM1 mutation status and our signature had an improved risk stratification ability (Figure 8g).

**Construction of nomogram predicting OS based on the cell cycle-related signature**

According to the rank in descending of risk scores, patients in TMA cohort were identically classified into three groups: high-risk, moderate-risk and low-risk. Kaplan–Meier survival analysis proved that patients at different risks presented distinct prognosis (Figure S7A). Patients were further stratified into subgroups of male and female, age ≤ 65 and ag > 65 years old, grade I/II and grade III/IV, stage I/II and stage III/IV. Except for the subgroup of stage III/IV (P = .24) and grade III/IV (P = .061), patients in high-risk group showed a better prognosis than those in moderate- and low-risk groups (Figure S7B–I).

The univariate and multivariate analysis were performed on the signature and clinicopathological factors to construct nomogram. In multivariate analysis, patients at higher risk according to the signature showed significantly shortened OS (moderate-risk: HR = 2.48, P = .042; high-risk: HR = 4.53, P < .001) compared to those at low risk (Figure 9a). The independent prognostic factors: AJCC stage, tumor size and Fuhrman grade were also incorporated into nomogram. A nomogram capable of predicting survival probabilities of ccRCC at 3, 5 and 8 years was finally built (Figure 9b). The C-index of nomogram was 0.81. The calibration curves at 3, 5 and 8 years showed good consistency between actual observation and the prediction by nomogram (Figure 9c-e). Time-dependent ROC showed that AUC of protein signature was 0.74, 0.75 and 0.72 at 3, 5 and 8 years. All AUCs of the gene signature were better at predicting survival probabilities than clinicopathological factors at each time point. Furthermore, nomogram had an obviously improved predictive accuracy of 0.89, 0.84 and 0.82 at 3, 5 and 8 years (Figure 9f-h).

**Discussion**

Cell cycle progress plays a crucial role in cell proliferation, the alteration of which has been recognized as the hallmark of oncogenesis. Recent studies indicate that cell cycle gene signatures show strong capacities of prognostication in many malignancies and have the potential of evaluating immunogenicity of tumors and their responses to ICIs. However, such relationship between cell cycle signatures and tumor immune microenvironment (TIME) in ccRCC was not reported before. In present study, we built a gene signature included two cell cycle genes (FOXM1&TOP2A) adopting DEGs from GEO database. The prognostic value of this signature was validated in three ccRCC cohorts: TCGA (n = 531), E-MTAB-1980 (n = 101) and TMA (n = 348) from our institution. Based on the signature, high-risk tumors present more aggressive biological behavior due to the high correlations with higher tumor grade and advanced pathologic stage. Furthermore, an immunosuppressive phenotype exits in high-risk tumors with more infiltrations of Tregs and tumor-associated macrophages (TAMs) accompany by high expressions of genes negatively regulating anti-tumor immune processes. In addition, we found low-risk tumors have an better response to nivolumab (anti-PD-1 agent) and compared to PD-L1, tumor mutation burden (TMB) and PBRM1 mutation, the cell cycle-related signature shows better ability in predicting response to immunotherapy.

In recent years, several gene signatures have been developed to evaluate the prognosis for ccRCC. These signatures containing multiple genes established from RNA-seq or RT-PCR data showed satisfactory predictive abilities, while none of them could utilized in clinical practice due to the high-condition analysis environment or lack of further validations. Detecting protein levels on TMA by IHC is a well-mastered and efficient method which is suitable for all tumor patients undergoing surgical resection. For the purpose of promotion in clinic, we constructed this cell cycle-related signature with good performance both in RNA-seq data (TCGA and
Our signature was proved to be the independent risk factor of ccRCC prognosis and a nomogram comprising this signature and clinicopathologic factors showed high AUCs (0.90 and 0.84 at 3 and 5 years) in predicting ccRCC survival outcomes.

Further investigation revealed the association between the cell cycle-related signature and TIME. In accordance with the theory tumor cells confer protection from immune surveillance by hyperactivation of cell cycle, high-risk tumors demonstrated a more suppressive immune phenotype due to higher cell abundance of infiltrate Tregs and TAMs. Regulatory T cells (Tregs) are immunosuppressive cells characterized by the expression of the FOXP3. Tregs can suppress immune activation via secreting immune suppressive...
cytokines (IL-10, IL-35, TGF-β), or expressing co-inhibitory molecules such as CTLA-4, PD-1, LAG-3 and TIGIT.\textsuperscript{57–49}

Tumor-associated macrophages (TAMs), presenting an M2-like polarization (anti-inflammatory), are the most abundant leucocyte subset in cancers.\textsuperscript{50} They are shaped by chemokines such as IL-4, IL10 and IL-13 to impede anti-tumor immunity.\textsuperscript{33,34} In the present study, CIBERSORT and IMMUNECELL AI were used to infer immune cell infiltrations in ccRCC. Tregs and TAMs are both upregulated in high-risk tumors deduced by two algorithms. We further proved this result by miHC detection of FOXP3+ Tregs and CD68+ CD163+ Macrophages in the TMA. In addition, cytokines (IL-4, IL-10, IL-13, TGF-β) participating in immunosuppressive process and co-inhibitory checkpoints (CTLA-4, PD-1 and LAG-3) were all upregulated in high-risk group, which validated the immunosuppression induced by Tregs/TAMs exists in high-risk tumors. Our findings show the great potential of our signature in predicting TIME of ccRCC, which might benefit the immunotherapy of such malignancy.

Nowadays, a substantial amount of clinical trials for immunotherapy are conducted across the world, which promotes the utilization of ICIs in ccRCC. Previous studies demonstrated that ccRCC patients could benefit from inhibition of immune checkpoints, such as CTLA-4 and PD-1/PD-L1. However, the response rates (5–12.5% to CTLA-4 inhibitor; 20–27% to PD-1 inhibitor) were relatively lower compared to other solid tumors (lung cancer, melanoma, etc).

Reliable biomarkers for immunotherapy response are desperately needed. Although PD-L1 has been the most promising biomarker of response to ICIs in most malignancies, its predictive value in ccRCC is controversial. Mori et al. reported that patients with PD-L1+ ccRCC tumors derived higher benefit from ICI combinations compared to PD-L1-ones.\textsuperscript{58} While results from the CHEKIMATE-025 trial of nivolumab versus everolimus in refractory mRCC demonstrate improvement in overall survival are consistent regardless of PD-L1 expression.\textsuperscript{5} TMB also serves as a potent predictor of ICIs response, while ccRCC generally carries low to moderate mutation load, the efficacy of this biomarker in ccRCC need more investigation.\textsuperscript{51} PBRM1 mutation is the second most common mutation in ccRCC according to TCGA database. PBRM1 LOF (loss of function), the specific biomarker in ccRCC, shows a strong correlation with improved survival in anti-PD-1 therapy. Thus, in present study, we tested the predictive value of PD-L1, TMB, PBRM1 LOF and the cell cycle-related signature in immunotherapy. The results show low-risk tumors according to the signature have improved responses to anti-PD-1 therapy ($P = 0.013$). PD-L1 expression and TMB are not associated with the efficacy of immunotherapy. PBRM1 LOF were more likely to
cluster in CB than NCB group (35.5% vs. 26.3%, \( P = .34 \)). Meanwhile, PBRM1 LOF is a protective factor for ccRCC survival. Incorporating PBRM1 LOF could enhance the abilities of risk stratification of our signature. Our study demonstrates this cell cycle-related signature is a promising and potent predictors of immunotherapy response in ccRCC.

Forkhead box M1 (FOXM1) is a transcriptional activator involved in cell proliferation and tumorigenesis. The encoded protein regulates the expression of several cell cycle genes, such as cyclin B1 and cyclin D1. Its overexpression has been reported in a diverse range of tumors. FOXM1 combined with CENPF can synergistically promote the malignant transformation of prostate cells and indicate poor prognosis of prostate cancer. TOP2A encodes topoisomerase IIα, a nuclear enzyme that controls DNA topological structure and promotes gene transcription during mitosis. Plenty of researches based on GEO or TCGA datasets have proved TOP2A is correlated with tumor progression and poor survival in ccRCC. Our research confirms the overexpression of TOP2A is associated with shortened OS and higher tumor grade in the TMA for the first time.

There are still some limitations in our research. Firstly, the TMA cohort only contains few patients with higher tumor grade (G3&G4) and pathologic stages (III&IV), which cause the failure in predicting ccRCC prognosis in those subgroups. Thus, data from multicentric cohorts with comprehensive clinical information are needed to confirm our findings. Secondly, although tissues in the TMA were selected from the area of tumor with the highest grade, which might represent the most aggressive subclones, the
known intratumor heterogeneity in RCC couldn’t be fully addressed. Thirdly, We only selected patients with RNA-seq data to analyze immunotherapy response in ccRCC, this selection bias might cause the inconsistence of PBRM1 LOF predicting abilities.

Overall, we developed a robust gene signature which could predict the prognosis of ccRCC. This signature reveals the close relationship between hyperactivation of cell cycle procession and immunosuppression in ccRCC for the first time. It also demonstrates a strong ability in predicting response to PD-1 blockade. Moreover, a nomogram developed based on the signature with a strong capacity of predicting ccRCC outcomes deserves promotion in clinical practice.

**Disclosure of potential conflicts of interest**

No potential conflict of interest was reported by the author(s).

**Funding**

No funding was received.
Ethics approval and consent to participate

Our study was approved by the Ethics and Research Committees of Renji Hospital, Shanghai Jiao Tong University School of Medicine.

References

1. Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3(1):17009. doi:10.1038/nrdp.2017.9.
2. Ljungberg B, Bansal K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyn MA, Lam T, Marconi L, Merseburger AS, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913–924. doi:10.1016/j.eururo.2015.01.005.
3. MacLennan S, Imamura M, Lapitan MC, Omar MI, Lam TBL, Hilvano-Cabungcal AM, Royle P, Stewart F, MacLennan G, MacLennan SJ, et al. Systematic review of oncological outcomes following surgical management of localised renal cancer. Eur Urol. 2012;61(5):972–993. doi:10.1016/j.eururo.2012.02.039.
4. Speed JM, Trinh QD, Choueiri TK, Sun M. Recurrence in localized renal cell carcinoma: a systematic review of contemporary data. Curr Urol Rep. 2017;18(2):15. doi:10.1007/s11934-017-0661-3.
5. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Somsean JA, Procopio G, Pimmack ER, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–1813. doi:10.1056/NEJMoa1510065.
6. Rini BI, Pimmack ER, Stus V, Gafanon R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulhières D, Melicar B, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–1127. doi:10.1056/NEJMoa1816714.
7. Motzer RJ, Pennkov K, Haansen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103–1115. doi:10.1056/NEJMoa1816047.
8. Simonaggio A, Epaulard N, Pobel C, Moreira M, Oudard S, Vano YA. Tumor microenvironment features as predictive biomarkers of response to immune checkpoint inhibitors (ICI) in metastatic clear cell renal cell carcinoma (mRCC). Cancers (Basel). 2021;13(2):231. doi:10.3390/cancers13020231.
9. Zhu N, Hou J. Assessing immune infiltration and the tumor microenvironment for the diagnosis and prognosis of sarcoma. Cancer Cell Int. 2020;20(1):577. doi:10.1186/s12935-020-01672-3.
10. Müller TJ, Anayaegbu CC, Lee-Pullen TF, Spalding LJ, Platell CF, McCoy MJ. PD-L1+ dendritic cells in the tumor microenvironment correlate with good prognosis and CD8+ T cell infiltration in colon cancer. Cancer Sci. 2021;112(3):1173–1183. doi:10.1111/cas.14781.
11. Brooks SA, Brannon AR, Parker JS, Fisher JC, Sen O, Kattan MW, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboi P, et al. ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma. Eur Urol. 2014;66(1):77–84. doi:10.1016/j.eururo.2014.02.035.
12. Rini B, Goddard A, Knezevic D, Maddala T, Zhou M, Aydin H, Campbell S, Elson P, Koscielny S, Lopatin M, et al. A 16-gene assay to predict recurrence after surgery in localized renal cell carcinoma: development and validation studies. Lancet Oncol. 2015;16(6):676–685. doi:10.1016/S1470-2045(15)70167-1.
13. Helminik BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577(7791):549–555. doi:10.1038/s41586-019-1922-8.
14. Gautier L, Cope L, Bolstad BM, Irizarry RA. affy - analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004;20(3):307–315. doi:10.1093/bioinformatics/btg405.
15. Carvalho BS, Irizarry RA. A framework for oligonucleotide microarray preprocessing. Bioinformatics. 2010;26(19):2363–2367. doi:10.1093/bioinformatics/btq431.
16. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. doi:10.1093/nar/gkv007.
17. Kolde R, Lauer S, Adler P, Vilo J. Robust rank aggregation for gene list integration and meta-analysis. Bioinformatics. 2012;28(4):573–580. doi:10.1093/bioinformatics/bts109.
18. Zhuang B, Horvath S. A general framework for weighted gene co-expression network analysis. Stat Appl Genet Mol Biol. 2005;4(1). doi:10.2202/1544-6115.1128.
19. Yin X, Wang J, Zhang J. Identification of biomarkers of chromophobe renal cell carcinoma by weighted gene co-expression network analysis. Cancer Cell Int. 2018;18(1):206. doi:10.1186/s12935-018-0703-z.
20. Ghi J, Li H. Penalized Cox regression analysis in the high-dimensional and low-sample size settings, with applications to microarray gene expression data. Bioinformatics. 2005;21(13):3001–3008. doi:10.1093/bioinformatics/bti422.
21. Yu GC, Wang LG, Han YY, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287. doi:10.1089/omi.2011.0118.
22. Hanelzmann S, Castelo R, Gunin G. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14(1):7. doi:10.1186/1471-2105-14-7.
23. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–+. doi:10.1038/nmeth.3337.
24. Miao YR, Zhang Q, Lei Q, Luo M, Xie G-Y, Wang H, Guo A-Y. ImmuneCellAI: a unique method for comprehensive T-cell subsets abundance prediction and its application in cancer immunotherapy. Adv Sci (Weih). 2020;7(9):1902880. doi:10.1002/ads.201902880.
25. Yoshihara K, Shahrmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW, Levine DA, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4(1):2612. doi:10.1038/ncomms3612.
26. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331(6024):1565–1570. doi:10.1126/science.1203486.
27. Charoentong P, Finotello F, Angelova M, Mayer C, Efremov M, Rieder D, Hackl H, Trajanoski Z. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248–262. doi:10.1016/j.celrep.2016.12.019.
28. Braun DA, Hou Y, Bakouny Z, Ficial M, Sant’ Angelo M, Forman J, Ross-Macdonald P, Berger AC, Jegede OA, Elagina L, et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020;26(6):909–918. doi:10.1038/s41591-020-0839-y.
29. Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized Phase II trial. J Clin Oncol. 2015;33(13):1430–1437. doi:10.1200/JCO.2014.59.0703.
30. Yuan L, Zeng G, Chen L, Wang G, Wang X, Cao X, Lu M, Liu X, Qian G, Xiao Y, et al. Identification of key genes and pathways in human clear cell renal cell carcinoma (ccRCC) by co-expression analysis. Int J Biol Sci. 2018;14(13):266–279. doi:10.7150/ijbs.23574.
31. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10. doi:10.1016/j.immuni.2013.07.012.

32. Xu L, Deng CY, Pang B, Zhang X, Liu W, Liao G, Yuan H, Cheng P, Li F, Long Z, et al. TIP: a web server for resolving tumor immunophenotype profiling. Cancer Res. 2018;78(23):6575–6580. doi:10.1158/0008-5472.CAN-18-0689.

33. Zhu ZY, Zhang HB, Chen BD, Liu X, Zhang S, Zong Z, Gao M. PD-L1-mediated immunosuppression in glioblastoma is associated with the infiltration and M2-polarization of tumor-associated macrophages. Front Immunol. 2020;11. doi:10.3389/fimmu.2020.08552.

34. Cheng H, Wang Z, Fu L, Xu T. Macrophage polarization in the development and progression of ovarian cancers: an overview. Front Oncol. 2019;9:421. doi:10.3389/fonc.2019.00421.

35. Carambia A, Freund B, Schwinge D, Heine M, Laschowitz A, Huber S, Wrath DC, Korn T, Schramm C, Lohse AW, et al. TGF-β-dependent induction of CD4+CD25+Foxp3+ Tregs by liver sinusoidal endothelial cells. J Hepatol. 2014;61(3):594–599. doi:10.1016/j.jhep.2014.04.027.

36. Miao D, Margolis CA, Gao W, Voss MH, Li W, Martini DJ, Norton C, Bosse D, Wankowicz SM, Cullen D, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801–806. doi:10.1126/science.aan5951.

37. Zhang C, Li Z, Qi F, Hu X, Luo J. Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma. Ann Transl Med. 2019;7(22):648. doi:10.21037/atm.2019.10.84.

38. Mori K, Abufaraj M, Mostafaei H, Quhal F, Fajkovic H, Remzi M, Karakiewicz PI, Egawa S, Schmidinger M, Shariat SF, et al. The predictive value of programmed death ligand 1 in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors: a systematic review and meta-analysis. Eur Urol. 2021;79(6):783–792. doi:10.1016/j.eurouro.2020.10.006.

39. Braun DA, Ishii Y, Walsh AM, Van Allen EM, Wu CJ, Shukla SA, Choueiri TK. Clinical validation of PBRM1 alterations as a marker of immune checkpoint inhibitor response in renal cell carcinoma. Jama Oncol. 2019;5(11):1631–1633. doi:10.1001/jamaoncol.2019.3158.

40. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70. doi:10.1016/S0092-8674(00)81683-9.

41. Shi R, Bao X, Rogowski P, Schäfer C, Schmidt-Hegemann N-S, Unger K, Lu S, Sun J, Buchner A, Stief C, et al. Establishment and validation of an individualized cell cycle process-related gene signature to predict cancer-specific survival in patients with bladder cancer. Cancers (Basel). 2020;12(5):1146. doi:10.3390/cancers12051146.

42. Oishi M, Takahashi T, Tokumaru Y, Yan L, Rashid OM, Matsumaya R, Endo I, Takabe K. G2M cell cycle pathway score as a prognostic biomarker of metastasis in Estrogen Receptor (ER)-positive breast cancer. Int J Mol Sci. 2020;21(8):2921. doi:10.3390/ijms21082921.

43. Petroni G, Formenti SC, Chen-Kiang S, Galluzzi L. Immunomodulation by anticancer cell cycle inhibitors. Nat Rev Immunol. 2020;20(11):669–679. doi:10.1038/s41577-020-0300-y.

44. Chen L, Luo Y, Wang G, Qian K, Qian G, Wu C-L, Dan HC, Wang X, Xiao Y. Prognostic value of a gene signature in clear cell renal cell carcinoma. J Cell Physiol. 2019;234(7):10324–10335. doi:10.1002/jcp.27700.

45. Li J, Stanger BZ. Cell cycle regulation meets tumor immunosuppression. Trends Immunol. 2020;41(10):859–863. doi:10.1016/j.it.2020.07.010.